This retrospective cohort study suggests that rituximab is more effective than conventional immunotherapy and might most impactful if initiated within 12 months of symptom onset in myasthenia gravis.
from Front page feed https://ift.tt/2T10jNg
from Front page feed https://ift.tt/2T10jNg
Comments
Post a Comment